2023 World Conference on Lung Cancer (Posters)-EP11.01. Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study

EP11.01. Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the outcomes of chemo-immunotherapy (CT-IT) as the first-line treatment for advanced lung adenocarcinoma (LUAC) patients in Italy. The study included 1068 patients from 33 Italian Centers. The median age of the patients was 66 years, and the majority were male current or former smokers. The study found that CT-IT was effective, with an overall response rate (ORR) of 43.4% in the overall population. The ORR varied based on PD-L1 expression, with rates of 38.8% in PD-L1 <1%, 47.0% in PD-L1 1-49%, and 42.1% in PD-L1 ≥50%. The most frequent site of disease progression was the lung, followed by bone. The median real-world progression-free survival (rwPFS) was 9.9 months, with variations based on PD-L1 expression: 9.6 months in PD-L1 <1%, 10.2 months in PD-L1 1-49%, and 8.7 months in PD-L1 ≥50%. The median overall survival (OS) was 16.1 months, with variations based on PD-L1 expression: 15.5 months in PD-L1 <1%, 16.6 months in PD-L1 1-49%, and 12.2 months in PD-L1 ≥50%. The 1-year rwPFS rate and 1-year OS rate were 44% and 60% respectively. Adverse events (AE) were experienced by 59.6% of patients, with the most common grade 3 AE being neutropenia and anemia. Overall, the study concluded that first-line CT-IT was effective and safe for advanced LUAC patients in the real-world setting, consistent with the findings from the KEYNOTE-189 registration study.

Asset Subtitle

Alessandro Leonetti

Meta Tag

Speaker Alessandro Leonetti

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

chemo-immunotherapy

CT-IT

lung adenocarcinoma

LUAC

Italy

overall response rate

PD-L1 expression

progression-free survival

overall survival

adverse events